Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Trigone Pharma Ltd. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are split between 2 distinct examiners and 2 distinct art units, showing a diversified approach to its patent filings. This distribution across different art units suggests that the company's pharmaceutical innovations may span multiple specialized subfields, requiring engagement with different sets of examination criteria.
PARK, HAEJIN S is the busiest examiner for the company. This examiner is currently handling 1 pending office action, while the total portfolio consists of 2 pending actions. With 2 distinct examiners involved, the company must navigate different examination styles simultaneously. This structure requires a versatile prosecution strategy that can adapt to the varied requirements of multiple examiners while maintaining consistency across the 2 pending office actions. The presence of 2 distinct art units further emphasizes the need for technical breadth in the company's legal responses to the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PARK, HAEJIN S | 1 | 55.0% | +38.4% |
| GOUGH, TIFFANY MAUREEN | 1 | 31.6% | +46.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701630 | COMPOSITIONS AND METHODS FOR DRUG INSTILLATION INTO THE URINARY BLADDER | PARK, HAEJIN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17606033 | FORMULATIONS AND METHODS FOR DRUG INSTILLATION INTO THE BLADDER AND TREATMENT OF BLADDER AILMENTS | GOUGH, TIFFANY MAUREEN | 30d overdue |
| 18701630 | COMPOSITIONS AND METHODS FOR DRUG INSTILLATION INTO THE URINARY BLADDER | PARK, HAEJIN S | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18701630 | COMPOSITIONS AND METHODS FOR DRUG INSTILLATION INTO THE URINARY BLADDER | PARK, HAEJIN S | 1614 | §103§112 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 17606033 | FORMULATIONS AND METHODS FOR DRUG INSTILLATION INTO THE BLADDER AND TREATMENT OF BLADDER AILMENTS | GOUGH, TIFFANY MAUREEN | 1651 | §103 | Non-Final OA | 30d overdue | Pending | Oct 24, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial